Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/22/26 Anthos Therapeutics abelacimab for Venous Thromboembolism (VTE) Subscribers Only Subscribers Only Subscribers Only
4/13/26 SynOx Therapeutics emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) / Pigmented Villonodular Synovitis (PVNS) Subscribers Only Subscribers Only Subscribers Only
4/13/26 Revolution Medicines (RVMD) daraxonrasib for Pancreatic Cancer Subscribers Only Subscribers Only Subscribers Only
4/11/26 Viatris (VTRS) Ryzumvi for Presbyopia Subscribers Only Subscribers Only Subscribers Only
4/7/26 NervGen Pharma (NGEN) NVG-291 for Spinal Cord Injury (SCI) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results